ALVIZON™ (fludrocortisone acetate) represents a novel class of agents for the treatment of eye disease.
Dry-AMD, and its end-stage, Geographic Atrophy (GA), involve inflammation and retinal pigmented epithelium (RPE) loss.
ALVIZON™’s unique mode of action targets nuclear receptors influencing blood-retinal barrier function and inflammatory pathways, including complement.
In Phase I and Phase II clinical studies, there was no evidence of sustained increase in IOP, no evidence of cataractogenesis, and no evidence of retinal toxicity.
Data from the Phase II study suggests that a three-monthly intravitreal injection is effective.
ALVIZON™ also demonstrated significant inhibition of GA lesion expansion.
